CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Compass Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$0.83−0.03 (-2.91%)

Close on Oct 19, 2026

Market cap: $155.98M
P/E (TTM): –
Dividend yield: –

Compass Therapeutics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	0	0.85	0	–	–	–	–
Research & Development	56	42	38	30	20	15	22
General & Administrative	17	15	12	12	11	13	12
Operating Expenses	73	57	50	42	82	28	34
Operating Income	-73	-57	-50	-42	-82	-28	-34
Interest Expense	–	–	–	0	0.37	0.91	1.23
Interest & Investment Income	6.40	7.30	7.90	2.36	0.03	0.09	0.74
Other Non-Operating Income	6.35	7.25	7.87	2.43	-0.30	-1.66	-0.60
Asset Impairment Charges	0	0	0	0	0	0	0
Gain (Loss) on Sale of Assets	–	–	0	0.07	0.04	-0.28	0
Pretax Income	–	–	-42	-39	-82	-29	-35
Income Tax Expense	0	0	0	0	0	0.03	0.09
Net Income incl. Noncontrolling Interests	–	–	–	–	-82	-30	-35
Net Income	-66	-49	-42	-39	-82	-30	-35
EPS (Basic)(per share)	-0.42	-0.36	-0.33	-0.37	-1.31	-0.96	-5.19
EPS (Diluted)(per share)	–	–	–	–	-1.31	-0.96	-5.19
Shares Outstanding (Basic, Weighted)(shares)	158	137	127	105	63	31	6.69
Shares Outstanding (Diluted, Weighted)(shares)	158	137	127	105	63	31	6.69
EBITDA	-73	-56	-50	-41	-81	-25	-32

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -41.3%

Financial strength

Current ratio: 11.22
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 219.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.94
Dividend yield: –